FedEx focuses on high-margin logistics business with new Life Sciences organization
Reading Time: 3 minutes
The new organization "FedEx Life Sciences” focuses on highly complex logistics for pharmaceuticals, medical devices, and clinical trials. The spin-off from FedEx Freight focuses on the core business. Revenues are expected to rise to 98 billion USD by 2029. Stephens analysts see a price target of 380 USD with a new transport cycle. Competitive pressure from Amazon remains a risk factor. FedEx (FDX) is sustainably transforming its business model to increasingly focus on growth-oriented, high-margin segments with specialized logistics...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
